Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis

Amrita Goyal; Daniel O'Leary; Kavita Goyal; Nathan Rubin; Kimberly Bohjanen; Maria Hordinsky; Steven T. Chen; Georgios Pongas; Lyn M. Duncan; Aleksandr Lazaryan

doi:10.1016/j.jaad.2019.07.075

Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis

Amrita Goyal, Daniel O'Leary, Kavita Goyal, Nathan Rubin, Kimberly Bohjanen, Maria Hordinsky, Steven T. Chen, Georgios Pongas, Lyn M. Duncan, Aleksandr Lazaryan

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

BACKGROUND: Mycosis fungoides (MF) is associated with increased risk of second primary hematologic malignancies, but its association with second primary solid tumors is less well characterized.

OBJECTIVE: This retrospective analysis seeks to assess the risk of being diagnosed with a second primary hematologic or solid malignancy in patients with MF.

DESIGN: We performed an analysis of patients diagnosed with MF from 2000 through 2015 in the United States cancer registries of SEER-18 (N = 6742).

RESULTS: Relative risks were estimated by using standardized incidence ratios (SIRs). Among 6742 patients, there were 511 (7.5%) second cancer events (SIR, 10.15; 95% confidence interval [CI], 9.29-11.07). These included 184 (36.0%) hematologic malignancies (SIR, 39.71; 95% CI, 34.05-46.05) and 327 (64.0%) solid tumor malignancies (SIR, 7.33; 95% CI, 6.56-8.17). Patients with MF were at increased risk for non-Hodgkin lymphoma; Hodgkin lymphoma; melanoma; and lung, female breast, prostate, colon, and renal cancers. Females were at higher risk than males (P < .05). All ethnic groups showed a statistically significant elevation in SIRs. Elevation of SIRs was observed across all stages of MF.

CONCLUSIONS AND RELEVANCE: Patients with MF are at increased risk for diagnosis of second primary malignancies and should be carefully screened for discernable signs and symptoms of second malignancies.

Original language	English (US)
Pages (from-to)	404-411
Number of pages	8
Journal	Journal of the American Academy of Dermatology
Volume	83
Issue number	2
DOIs	https://doi.org/10.1016/j.jaad.2019.07.075
State	Published - Aug 2020

Bibliographical note

Funding Information:
Funding sources: Supported by an HONORS (Hematology Opportunities for the Next Generation of Research Scientists) award research grant from the American Society of Hematology. Statistical analysis was in part supported by National Institutes of Health grant P30 CA77598 usign the Biostatistics and Bioinformatics Core shared resource of the Masonic Cancer Center, University of Minnesota and by the National Center for Advancing Translational Sciences of the National Institutes of Health award number UL1TR000114. This funded the statistical analysis. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.We would like to thank the American Society of Hematology for supporting this study as part of the HONORS (Hematology Opportunities for the Next Generation of Research Scientists) award research grant. We appreciate Michael Franklyn's editorial contributions.

Funding Information:
We would like to thank the American Society of Hematology for supporting this study as part of the HONORS (Hematology Opportunities for the Next Generation of Research Scientists) award research grant. We appreciate Michael Franklyn's editorial contributions.

Publisher Copyright:
© 2019 American Academy of Dermatology, Inc.

Keywords

CTCL
SEER
Surveillance Epidemiology and End Results
cutaneous T-cell lymphoma
cutaneous lymphoma
mycosis fungoides
non-Hodgkin lymphoma
second malignancy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.jaad.2019.07.075

Find It

Find It at U of M Libraries

Cite this

Goyal, A., O'Leary, D., Goyal, K., Rubin, N., Bohjanen, K., Hordinsky, M., Chen, S. T., Pongas, G., Duncan, L. M., & Lazaryan, A. (2020). Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis. Journal of the American Academy of Dermatology, 83(2), 404-411. https://doi.org/10.1016/j.jaad.2019.07.075

Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis. / Goyal, Amrita; O'Leary, Daniel; Goyal, Kavita et al.
In: Journal of the American Academy of Dermatology, Vol. 83, No. 2, 08.2020, p. 404-411.

Research output: Contribution to journal › Article › peer-review

Goyal, A, O'Leary, D, Goyal, K, Rubin, N , Bohjanen, K , Hordinsky, M, Chen, ST, Pongas, G, Duncan, LM & Lazaryan, A 2020, 'Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis', Journal of the American Academy of Dermatology, vol. 83, no. 2, pp. 404-411. https://doi.org/10.1016/j.jaad.2019.07.075

@article{f8de72eb11f244d4a7d26aee74615e5b,

title = "Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis",

abstract = "BACKGROUND: Mycosis fungoides (MF) is associated with increased risk of second primary hematologic malignancies, but its association with second primary solid tumors is less well characterized.OBJECTIVE: This retrospective analysis seeks to assess the risk of being diagnosed with a second primary hematologic or solid malignancy in patients with MF.DESIGN: We performed an analysis of patients diagnosed with MF from 2000 through 2015 in the United States cancer registries of SEER-18 (N = 6742).RESULTS: Relative risks were estimated by using standardized incidence ratios (SIRs). Among 6742 patients, there were 511 (7.5%) second cancer events (SIR, 10.15; 95% confidence interval [CI], 9.29-11.07). These included 184 (36.0%) hematologic malignancies (SIR, 39.71; 95% CI, 34.05-46.05) and 327 (64.0%) solid tumor malignancies (SIR, 7.33; 95% CI, 6.56-8.17). Patients with MF were at increased risk for non-Hodgkin lymphoma; Hodgkin lymphoma; melanoma; and lung, female breast, prostate, colon, and renal cancers. Females were at higher risk than males (P < .05). All ethnic groups showed a statistically significant elevation in SIRs. Elevation of SIRs was observed across all stages of MF.CONCLUSIONS AND RELEVANCE: Patients with MF are at increased risk for diagnosis of second primary malignancies and should be carefully screened for discernable signs and symptoms of second malignancies.",

keywords = "CTCL, SEER, Surveillance Epidemiology and End Results, cutaneous T-cell lymphoma, cutaneous lymphoma, mycosis fungoides, non-Hodgkin lymphoma, second malignancy",

author = "Amrita Goyal and Daniel O'Leary and Kavita Goyal and Nathan Rubin and Kimberly Bohjanen and Maria Hordinsky and Chen, {Steven T.} and Georgios Pongas and Duncan, {Lyn M.} and Aleksandr Lazaryan",

note = "Funding Information: Funding sources: Supported by an HONORS (Hematology Opportunities for the Next Generation of Research Scientists) award research grant from the American Society of Hematology. Statistical analysis was in part supported by National Institutes of Health grant P30 CA77598 usign the Biostatistics and Bioinformatics Core shared resource of the Masonic Cancer Center, University of Minnesota and by the National Center for Advancing Translational Sciences of the National Institutes of Health award number UL1TR000114. This funded the statistical analysis. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.We would like to thank the American Society of Hematology for supporting this study as part of the HONORS (Hematology Opportunities for the Next Generation of Research Scientists) award research grant. We appreciate Michael Franklyn's editorial contributions. Funding Information: We would like to thank the American Society of Hematology for supporting this study as part of the HONORS (Hematology Opportunities for the Next Generation of Research Scientists) award research grant. We appreciate Michael Franklyn's editorial contributions. Publisher Copyright: {\textcopyright} 2019 American Academy of Dermatology, Inc.",

year = "2020",

month = aug,

doi = "10.1016/j.jaad.2019.07.075",

language = "English (US)",

volume = "83",

pages = "404--411",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "2",

}

TY - JOUR

T1 - Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides

T2 - A Surveillance, Epidemiology, and End Results analysis

AU - Goyal, Amrita

AU - O'Leary, Daniel

AU - Goyal, Kavita

AU - Rubin, Nathan

AU - Bohjanen, Kimberly

AU - Hordinsky, Maria

AU - Chen, Steven T.

AU - Pongas, Georgios

AU - Duncan, Lyn M.

AU - Lazaryan, Aleksandr

N1 - Funding Information: Funding sources: Supported by an HONORS (Hematology Opportunities for the Next Generation of Research Scientists) award research grant from the American Society of Hematology. Statistical analysis was in part supported by National Institutes of Health grant P30 CA77598 usign the Biostatistics and Bioinformatics Core shared resource of the Masonic Cancer Center, University of Minnesota and by the National Center for Advancing Translational Sciences of the National Institutes of Health award number UL1TR000114. This funded the statistical analysis. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.We would like to thank the American Society of Hematology for supporting this study as part of the HONORS (Hematology Opportunities for the Next Generation of Research Scientists) award research grant. We appreciate Michael Franklyn's editorial contributions. Funding Information: We would like to thank the American Society of Hematology for supporting this study as part of the HONORS (Hematology Opportunities for the Next Generation of Research Scientists) award research grant. We appreciate Michael Franklyn's editorial contributions. Publisher Copyright: © 2019 American Academy of Dermatology, Inc.

PY - 2020/8

Y1 - 2020/8

N2 - BACKGROUND: Mycosis fungoides (MF) is associated with increased risk of second primary hematologic malignancies, but its association with second primary solid tumors is less well characterized.OBJECTIVE: This retrospective analysis seeks to assess the risk of being diagnosed with a second primary hematologic or solid malignancy in patients with MF.DESIGN: We performed an analysis of patients diagnosed with MF from 2000 through 2015 in the United States cancer registries of SEER-18 (N = 6742).RESULTS: Relative risks were estimated by using standardized incidence ratios (SIRs). Among 6742 patients, there were 511 (7.5%) second cancer events (SIR, 10.15; 95% confidence interval [CI], 9.29-11.07). These included 184 (36.0%) hematologic malignancies (SIR, 39.71; 95% CI, 34.05-46.05) and 327 (64.0%) solid tumor malignancies (SIR, 7.33; 95% CI, 6.56-8.17). Patients with MF were at increased risk for non-Hodgkin lymphoma; Hodgkin lymphoma; melanoma; and lung, female breast, prostate, colon, and renal cancers. Females were at higher risk than males (P < .05). All ethnic groups showed a statistically significant elevation in SIRs. Elevation of SIRs was observed across all stages of MF.CONCLUSIONS AND RELEVANCE: Patients with MF are at increased risk for diagnosis of second primary malignancies and should be carefully screened for discernable signs and symptoms of second malignancies.

AB - BACKGROUND: Mycosis fungoides (MF) is associated with increased risk of second primary hematologic malignancies, but its association with second primary solid tumors is less well characterized.OBJECTIVE: This retrospective analysis seeks to assess the risk of being diagnosed with a second primary hematologic or solid malignancy in patients with MF.DESIGN: We performed an analysis of patients diagnosed with MF from 2000 through 2015 in the United States cancer registries of SEER-18 (N = 6742).RESULTS: Relative risks were estimated by using standardized incidence ratios (SIRs). Among 6742 patients, there were 511 (7.5%) second cancer events (SIR, 10.15; 95% confidence interval [CI], 9.29-11.07). These included 184 (36.0%) hematologic malignancies (SIR, 39.71; 95% CI, 34.05-46.05) and 327 (64.0%) solid tumor malignancies (SIR, 7.33; 95% CI, 6.56-8.17). Patients with MF were at increased risk for non-Hodgkin lymphoma; Hodgkin lymphoma; melanoma; and lung, female breast, prostate, colon, and renal cancers. Females were at higher risk than males (P < .05). All ethnic groups showed a statistically significant elevation in SIRs. Elevation of SIRs was observed across all stages of MF.CONCLUSIONS AND RELEVANCE: Patients with MF are at increased risk for diagnosis of second primary malignancies and should be carefully screened for discernable signs and symptoms of second malignancies.

KW - CTCL

KW - SEER

KW - Surveillance Epidemiology and End Results

KW - cutaneous T-cell lymphoma

KW - cutaneous lymphoma

KW - mycosis fungoides

KW - non-Hodgkin lymphoma

KW - second malignancy

UR - http://www.scopus.com/inward/record.url?scp=85073719817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073719817&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2019.07.075

DO - 10.1016/j.jaad.2019.07.075

M3 - Article

C2 - 31374302

AN - SCOPUS:85073719817

SN - 0190-9622

VL - 83

SP - 404

EP - 411

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 2

ER -

Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this